SCHEMBL19929587

SCHEMBL19929587

N[C@@H](CCCCNC(=O)CCc1ccc([125I])cc1)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.49
POLB P06746 1/20 0.46
ALB P02768 3/20 0.46
PYGL P06737 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
LMNA P02545 2/20 0.44
KDM4E B2RXH2 1/20 0.44
OTC P00480 1/20 0.44
KEAP1 Q14145 1/20 0.43
NFE2L2 Q16236 1/20 0.43
MMP1 P03956 1/20 0.43
MMP2 P08253 1/20 0.43
MMP3 P08254 1/20 0.43
MMP7 P09237 1/20 0.43
MMP9 P14780 1/20 0.43
MMP13 P45452 1/20 0.43
TSHR P16473 1/20 0.43
SLC5A1 P13866 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19929579 0.94 ALB (0.53) ALBL3MBTL1LMNATSHRSLC5A1
SCHEMBL6014960 0.88 HPGD (0.63) HPGDL3MBTL1LMNAKDM4EKEAP1
SCHEMBL19929582 0.88 FOLH1 (0.41) HPGDALBOTCSLC5A1FOLH1
SCHEMBL31711037 0.87 HPGD (0.50) HPGDPOLBALBPYGLL3MBTL1
SCHEMBL19929577 0.87 HPGD (0.49) HPGDPOLBALBPYGLL3MBTL1
SCHEMBL19924294 0.87 ALB (0.60) HPGDPOLBALBPYGLL3MBTL1
SCHEMBL19933090 0.87 ALB (0.60) HPGDPOLBALBPYGLL3MBTL1
SCHEMBL19929585 0.87 HPGD (0.49) HPGDPOLBALBPYGLL3MBTL1
SCHEMBL19929576 0.87 HPGD (0.49) HPGDPOLBALBPYGLL3MBTL1
SCHEMBL31268361 0.85 HPGD (0.49) HPGDPOLBALBL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230332199-A1 FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS RATIO THERAPEUTICS, INC. 2023-10-19 US disclosed
US-20180066298-A1 FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS RATIO THERAPEUTICS, INC. 2018-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230332199-A1 FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS IL1RN, IL2RA, IL1A HPGD 1284/4885POLB 3619/4885ALB 31/4885
US-20180066298-A1 FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS IL1RN, IL2RA, IL1A HPGD 1284/4885POLB 3619/4885ALB 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.